BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2715 related articles for article (PubMed ID: 7894087)

  • 21. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity.
    Regenass U; Mett H; Stanek J; Mueller M; Kramer D; Porter CW
    Cancer Res; 1994 Jun; 54(12):3210-7. PubMed ID: 8205541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Analysis of the chemosensitivity test by subrenal capsule assay].
    Terashima M; Ikeda K; Satoh M; Ishida K; Yoshida H; Mori S; Inada K; Yoshida M
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):653-8. PubMed ID: 2435246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
    Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective accumulation of the endoplasmic reticulum-Golgi intermediate compartment induced by the antitumor drug KRN5500.
    Kamishohara M; Kenney S; Domergue R; Vistica DT; Sausville EA
    Exp Cell Res; 2000 May; 256(2):468-79. PubMed ID: 10772819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor activity and toxicity in animals of RR-150 (7-cysteaminomitosane), a new mitomycin derivative.
    Bradner WT; Rose WC; Schurig JE; Schlein A; Huftalen JB
    Cancer Res; 1984 Dec; 44(12 Pt 1):5619-23. PubMed ID: 6437670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
    Rice JR; Gerberich JL; Nowotnik DP; Howell SB
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2248-54. PubMed ID: 16609041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
    Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines.
    Glinsky GV; Price JE; Glinsky VV; Mossine VV; Kiriakova G; Metcalf JB
    Cancer Res; 1996 Dec; 56(23):5319-24. PubMed ID: 8968076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor activity of SPM VIII, a derivative of the nucleoside antibiotic spicamycin, against human tumor xenografts.
    Kamishohara M; Kawai H; Odagawa A; Isoe T; Mochizuki J; Uchida T; Hayakawa Y; Seto H; Tsuruo T; Otake N
    J Antibiot (Tokyo); 1994 Nov; 47(11):1305-11. PubMed ID: 8002395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor activity and toxicity in animals of BMY-25282, a new mitomycin derivative.
    Bradner WT; Rose WC; Schurig JE; Florczyk AP; Huftalen JB; Catino JJ
    Cancer Res; 1985 Dec; 45(12 Pt 1):6475-81. PubMed ID: 3933826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Experimental studies on subrenal capsule assay using cyclosporin A treated mice--the optimal treatment schedules of CsA and anticancer agents (mitomycin C and 5-fluorouracil)].
    Kusuyama T; Okuyama Y; Fujita M; Taguchi T
    Gan To Kagaku Ryoho; 1990 Feb; 17(2):259-67. PubMed ID: 2105699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experimental tumor inhibitory and toxic properties of the mitomycin A analogue 7-(2-hydroxyethoxy) mitosane (BMY-25551).
    Bradner WT; Catino JJ; Long BH; Rose WC; Schurig JE
    Anticancer Res; 1992; 12(3):959-64. PubMed ID: 1622154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion.
    Bernacki RJ; Oberman EJ; Seweryniak KE; Atwood A; Bergeron RJ; Porter CW
    Clin Cancer Res; 1995 Aug; 1(8):847-57. PubMed ID: 9816054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spicamycin and KRN5500 induce apoptosis in myeloid and lymphoid cell lines with down-regulation of bcl-2 expression and modulation of promyelocytic leukemia protein.
    Zhang WJ; Ohnishi K; Yoshida H; Pan L; Maksumova L; Muratkhodjaev F; Luo JM; Shigeno K; Fujisawa S; Naito K; Nakamura S; Shinjo K; Takeshita A; Ohno R
    Jpn J Cancer Res; 2000 Jun; 91(6):604-11. PubMed ID: 10874212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative study on the anticancer activities of KW2149 and mitomycin C against human tumor xenografts using subrenal capsule assay].
    Takagami S; Nishiyama M; Kim R; Kirihara Y; Jinushi K; Saeki K; Saeki T; Nosoh Y; Niimoto M; Hattori T
    Gan To Kagaku Ryoho; 1989 Jun; 16(6):2189-93. PubMed ID: 2500067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
    Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
    Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
    Cao S; McGuire JJ; Rustum YM
    Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
    Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
    J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 136.